May 19th 2024
With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.
Extreme Glycemic Control Not Significantly Associated with Increased All-Cause Mortality
June 24th 2013While the current ADA guidelines recommend targeting HbA1c levels to below 8% for high-risk patients with diabetes, reducing the level to 5.7% dose not raise CVD or overall mortality risk, according to a recent study.
Combination Liraglutide and Insulin Degludec Is Safe and Effective in Type 2 Diabetes
June 23rd 2013Study shows a combination of liraglutide and the genetically modified insulin analog degludec was safe and improved HbA1c levels, weight loss, and hypoglycemia outcomes in patients with type 2 diabetes.
The Educated Patient® Diabetes Resource Guide
June 21st 2013The Diabetes Resource Guide highlights 20 websites that feature articles on topics such as ways to address and improve lifestyle factors (such as diet), how to live day to day with diabetes, information about diabetes medications, online forums, and more.
Nonalcoholic Fatty Liver Disease Boosts Cardiovascular Risk, But Lacks Management Plan
May 21st 2013Growing evidence suggests increased cardiovascular risk in patients with nonalcoholic fatty liver disease (NAFLD) - in particular nonalcoholic steatohepatitis (NASN) - but no data exists to support a specific management approach.
New Diabetes Management Guidelines Consider Concurrent Conditions
In diagnosing a patient with type 2 diabetes, an endocrinologist or primary care physician may struggle with developing healthy treatment targets when comorbid conditions like obesity and hypoglycemia are at play.
Looking for Effective Treatment Options for Painful Diabetic Peripheral Neuropathy
March 23rd 2013Severe neuropathic pain due to diabetic peripheral neuropathy is associated with negative health impact and increased healthcare utilization, underscoring the need for the development of safe and effective treatments.
FREEDOM Study Reveals CABG is More Cost-Effective than PCI for Patients with Diabetes
November 6th 2012Study results presented at AHA 2012 indicate that revascularization using CABG in diabetic patients with multivessel disease provides better clinical outcomes than PCI and is more cost effective in the long run.
Chelation Therapy Does not Improve Quality of Life in Treated Heart Attack Patients
November 6th 2012Results from a sub-study of the Trial to Assess Chelation Therapy (TACT) that focused on quality of life issues in patients who had previously suffered a heart attack and were treated with chelation therapy reveal no improvements in these patients' quality of life.